[18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma

被引：0
|
作者：
Ziyuan Zhu
Kai Cheng
Zhang Yun
Xiang Zhang
Xiaoyu Hu
Jing Liu
Fuhao Wang
Zheng Fu
Jinbo Yue
机构：
[1] Weifang Medical University,School of Clinical Medicine
[2] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Radiation Oncology, Shandong Cancer Hospital and Institute
[3] Shandong First Medical University,PET/CT Center, Shandong Cancer Hospital and Institute
[4] Shandong Academy of Medical Sciences,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Fibroblast activation protein; Pancreatic adenocarcinoma; Metabolic tumor volume; Total lesion FAP expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3425 / 3438
页数：13
相关论文
共 50 条
  • [1] [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma
    Zhu, Ziyuan
    Cheng, Kai
    Yun, Zhang
    Zhang, Xiang
    Hu, Xiaoyu
    Liu, Jing
    Wang, Fuhao
    Fu, Zheng
    Yue, Jinbo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (11) : 3425 - 3438
  • [2] Value of [18F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy
    Zhang, Yafei
    Xu, Mimi
    Wang, Yu
    Yu, Fang
    Chen, Xinxin
    Wang, Guangfa
    Zhao, Kui
    Yang, Hong
    Su, Xinhui
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [3] 18F-A1F-NOTA-FAPI-04 PET/CT can Predict Treatment Response and Survival in Patients with Inoperable Pancreatic Adenocarcinoma
    Zhu, Z.
    Zhang, X.
    Zhang, Y.
    Hu, X.
    Yue, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E360 - E360
  • [4] [18F]AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
    Hu, X.
    Yu, J.
    Wei, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S225 - S225
  • [5] Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT
    Lv, Jinghui
    Zheng, Kai
    Jiang, Chengzhi
    Yang, Jian
    Peng, Xiang
    Ye, Hui
    Zhang, Yanyin
    EUROPEAN RADIOLOGY, 2024,
  • [6] [18F]AlF-NOTA-FAPI-04 PET/CT: A Promising Tool for Discriminating Benign and Malignant Breast Lesions
    Liu, Tianxin
    Liu, Jingru
    Zhao, Kunlong
    Yu, Jinming
    Liu, Jie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [7] Early detection of radiation-induced myocardial damage by [18F]AlF-NOTA-FAPI-04 PET/CT imaging
    Wei, Yuchun
    Sun, Yuhong
    Liu, Junyan
    Zhang, Gongsen
    Qin, Xueting
    Xu, Shengnan
    Wang, Shijie
    Tao, Yuanyuan
    Pei, Jinli
    Yu, Jinming
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (02) : 453 - 464
  • [8] Value of [18F]AlF-NOTA-FAPI-04 PET/CT for differential diagnosis of malignant and various inflammatory lung lesions: comparison with [18F]FDG PET/CT
    Kailin Qiao
    Xueting Qin
    Shuai Fu
    Jiazhong Ren
    Jing Jia
    Xinying Hu
    Yuanyuan Tao
    Shuanghu Yuan
    Yuchun Wei
    European Radiology, 2024, 34 : 1948 - 1959
  • [9] [18F] AlF-NOTA-FAPI-04 PET/CT for non-invasive assessment of tubular injury in kidney diseases
    Wang, Hao
    Zhang, Ping
    Wang, Wei
    He, Limeng
    Liu, Nan
    Yang, Juan
    Tang, Deying
    Li, Guisen
    Feng, Yunlin
    Zhang, Wei
    CLINICAL KIDNEY JOURNAL, 2024, 17 (05)
  • [10] [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers
    Yuchun Wei
    Jinsong Zheng
    Li Ma
    Xiaoli Liu
    Shengnan Xu
    Shijie Wang
    Jinli Pei
    Kai Cheng
    Shuanghu Yuan
    Jinming Yu
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 2761 - 2773
12345